Eisai Co-establishes the Global Health Innovative Technology Fun

Eisai Co-establishes the Global Health Innovative Technology Fund 
Aims to Advance Development of New Health Tech for the Developing World 
Tokyo, Apr 8, 2013 - (JCN Newswire) -  Eisai Co., Ltd. has co-established the
Global Health Innovative Technology Fund (GHIT Fund) to advance the research
and development of new medicines, vaccines, and diagnostics from Japan to fight
infectious diseases in emerging countries and the developing world. 
The GHIT Fund is the first public-private partnership in Japan dedicated to
the field of global health. It is a partnership between Eisai and four other
Japanese pharmaceutical companies, the Government of Japan and the Bill &
Melinda Gates Foundation. The GHIT Fund will facilitate global partnerships
between Japanese and non-Japanese research and development organizations and
fund promising research programs in order to realize advances in new health
technologies by Japanese pharmaceutical companies, universities and research
institutions possessing strengths in drug creation, with the aim of utilizing
those technologies effectively in emerging countries and the developing world. 
Eisai is committed to contributing to the improvement of public healthcare for
peoples in emerging countries and the developing world and the expansion of
economic development, the middle class and other factors that may benefit those
regions. The company considers this commitment as a long-term investment in its
future in an increasingly globalized era and as such consistently engages in
initiatives focused on overcoming issues related to access to medicines in
order to effectively combat infectious diseases, including neglected tropical
diseases (NTDs). Eisai expects the establishment of the GHIT Fund to lead to
further global public-private partnerships focused on the development of new
drugs and contribute to global health through advances made in new health
technologies in Japan. 
Eisai is also a signatory to the London Declaration, which is the largest
global public-private partnership to date and aims to eliminate ten NTDs by
2020. As part of its commitment under the declaration, Eisai has agreed to
produce at its Vizag Plant in India 2.2 billion tablets of the lymphatic
filariasis medicine diethylcarbamazine (DEC) and supply them to the World
Health Organization (WHO) at price zero. Furthermore, the company is moving
ahead with new drug development projects targeting malaria and NTDs such as
Chagas disease and leishmaniasis, based on partnerships with international
non-profit organizations such as the Drugs for Neglected Diseases initiative
(DNDi ) and Sabin Vaccine Institute as well as Brazil's national research
agency, the FundaCao Oswaldo Cruz. 
The company remains actively committed to continuing the above and other
initiatives to ensure access to medicines in emerging countries and the
developing world in order to better contribute to increasing the benefits
provided to patients and their families in those regions. 
About the Global Health Innovative Technology Fund (GHIT Fund) 
The Global Health Innovative Technology Fund (GHIT Fund) is an international
non-profit organization aimed to advance the research and development (R&D)
of new health technologies from Japan to fight infectious diseases prevalent
specifically in the developing world, including HIV/AIDS, malaria,
tuberculosis, and neglected tropical diseases (NTDs). Established as a
public-private partnership between the Government of Japan, a consortium of
pharmaceutical companies and the Bill & Melinda Gates Foundation, the GHIT
Fund facilitates and funds the R&D of new health technologies through
partnership creation and grant-making activities. To learn more about the GHIT
Fund, please see www.ghitfund.org. 
About Neglected Tropical Diseases (NTDs) 
According to the World Health Organization (WHO), NTDs* blight the lives of
more than 1 billion of the world's poorest 2.7 billion people. There are
149 countries and territories where NTDs are endemic, at least 100 of which are
endemic for 2 or more of these diseases, and 30 countries that are endemic for
6 or more. These diseases not only survive and spread in conditions of poverty;
they also anchor large populations in poverty. 
* NTDs designated by the WHO for control or elimination: Buruli ulcer, Chagas
disease (American trypanosomiasis), cysticercosis / taeniasis, dengue / severe
dengue, dracunculiasis (Guinea worm disease), echinococcosis, fascioliasis,
human African trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis,
onchocerciasis, rabies, schistosomiasis, soil-transmitted helminthiasis,
trachoma, and yaws. 
About Eisai's Commitment to Improving Global Access to Medicines 
Today, it is estimated that some 2.7 billion people around the world live on
US$2 or less per day. Most of these 2.7 billion people do not have access to
essential healthcare and treatment despite the availability of effective
medicines. This is an international challenge that needs to be solved through
collaborations among governments, international organizations such as the World
Health Organization (WHO), non-governmental organizations, and pharmaceutical
companies. In line with its human health care (hhc) mission, Eisai is committed
to improving global access to medicines over the medium-to-long term through
partnership strategies that involve working with governments, international
organizations, private entities, and non-profit organizations. As part of these
efforts, the company has agreed to provide the medicine diethylcarbamazine
(DEC) free of charge to the WHO in support of its program to eliminate the NTD
lymphatic filariasis, and is also engaged in a research collaboration with an
international non-profit foundation to develop the new drug E1224 (a prodrug of
ravuconazole) for the treatment of Chagas disease. For further information on
Eisai’s Access to Medicines initiatives, please visit the Access to Medicines
page on the Eisai global website: http://www.eisai.com/company/atm/index.html. 
About Eisai 
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com. 
Contact: 
Eisai Co., Ltd.
Public Relations Department
Tel: +81-3-3817-5120 
For media inquiries regarding the GHIT Fund: 
Global Health Innovative Technology Fund
PR office (COSMO PR),
Maruan El Mahgiub
Tel: +81-3-5561-2915 / Fax: +81-3-5561-2912
Email: press@ghitfund.org 
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net 
Provider ID: 00026563
 
 
Press spacebar to pause and continue. Press esc to stop.